Deprecated

Executive Summary

The Legit.Health medical device delivers quantifiable value of €146.43 per patient annually through clinical efficiency improvements, diagnostic quality enhancement, early intervention capabilities, system capacity optimization, patient experience benefits, and risk mitigation.

Based on this value generation and healthcare industry benchmarks for value capture (20-30% of generated value), we recommend:

• Comprehensive Model Pricing: €40-48 per patient/year (delivering 205-266% ROI)
• Conservative Model Pricing: €29-36 per patient/year (delivering 198-270% ROI)

The conservative model focuses exclusively on healthcare system benefits (€107.33), excluding patient-direct benefits and risk mitigation value.

Value Calculation Summary

$$\begin{aligned} \mathrm{Comprehensive~Value} &= \sum_{i=1}^{6} \mathrm{Category}_i = 146.43~\mathrm{EUR~per~patient~annually} \\ \mathrm{Conservative~Value} &= \sum_{i=1}^{4} \mathrm{Category}_i = 107.33~\mathrm{EUR~per~patient~annually} \end{aligned}$$

Pricing Recommendation

$$\begin{aligned} \mathrm{Standard~Price} &= 146.43 \times 0.30 = 43.93~\mathrm{EUR}~(30\%~\mathrm{value~capture}) \\ \mathrm{Conservative~Price} &= 107.33 \times 0.30 = 32.20~\mathrm{EUR}~(30\%~\mathrm{value~capture}) \end{aligned}$$

Category 1: Clinical Efficiency Value (€42.85)

Referral Optimization Through Triage Accuracy: €12.43

The device improves triage accuracy by 14%¹, reducing inappropriate specialist referrals from primary care. Based on Valencia healthcare benchmarks², this optimization generates:

$$\begin{aligned} \mathrm{Referral Value} &= \mathrm{Accuracy Gain} \times \mathrm{Referrals} \times \mathrm{Cost Differential} \\ &= 0.14 \times 2.4 \times (74.00 - 56.95)\mathrm{ EUR} \\ &= 0.14 \times 2.4 \times 17.05 = 5.73\mathrm{ EUR} \end{aligned}$$

Additionally, the device empowers primary care physicians to manage 49-55% more dermatology cases directly³, reducing specialist dependency:

$$\begin{aligned} \mathrm{PCP Empowerment} &= \mathrm{Cases Retained} \times \mathrm{Specialist Cost} \times \mathrm{Attribution} \\ &= 0.52 \times 74.00\mathrm{ EUR} \times \frac{2.4}{13.2} = 6.70\mathrm{ EUR} \end{aligned}$$

Total Referral Optimization: €5.73 + €6.70 = €12.43

Documentation Efficiency: €8.22

Automated report generation reduces documentation time by 63%, from 8 minutes to 3 minutes per consultation⁴. For a specialist earning €93.84 per consultation:

$$\begin{aligned} \mathrm{Documentation Value} &= \mathrm{Time Saved} \times \mathrm{Value Rate} \times \mathrm{Annual Reports} \\ &= 5\mathrm{ min} \times \frac{93.84\mathrm{ EUR}}{60\mathrm{ min}} \times 2.4 \times \mathrm{Efficiency Factor} \\ &= 7.82 \times 1.05 = 8.22\mathrm{ EUR} \end{aligned}$$

Remote Care Enablement: €5.45

Clinical studies demonstrate 44-53% of dermatology consultations can be resolved remotely⁵⁶:

$$\begin{aligned} \mathrm{Remote Value} &= \mathrm{Remote Resolution Rate} \times \mathrm{Visit Cost} \times \mathrm{Capture Rate} \\ &= 0.485 \times 37.00\mathrm{ EUR} \times 0.304 = 5.45\mathrm{ EUR} \end{aligned}$$

Second Opinion Reduction: €7.32

Improved diagnostic concordance from 72% to 86%⁷ reduces unnecessary second opinions:

$$\begin{aligned} \mathrm{Second Opinion Savings} &= \mathrm{Reduced Consultations} \times \mathrm{Consultation Cost} \\ &= 0.14 \times 2.4 \times 37.00\mathrm{ EUR} \times 0.62 = 7.32\mathrm{ EUR} \end{aligned}$$

Treatment Optimization Through Severity Assessment: €8.45

The device provides objective severity scoring (ICC 0.7-0.9)⁸, reducing treatment variability:

$$\begin{aligned} \mathrm{Treatment Value} &= \mathrm{Variability Reduction} \times \mathrm{Annual Treatment Cost} \times \mathrm{Efficiency} \\ &= 0.40 \times 845\mathrm{ EUR} \times 0.025 = 8.45\mathrm{ EUR} \end{aligned}$$

Regulatory Compliance Automation: €3.43

Automated compliance with regulatory requirements saves administrative time:

$$\begin{aligned} \mathrm{Compliance Value} &= \mathrm{Admin Time Saved} \times \mathrm{Hourly Rate} \times \mathrm{Annual Frequency} \\ &= 4\mathrm{ hours} \times \frac{45\mathrm{ EUR}}{\mathrm{hour}} \times \frac{2.4}{12.5} = 3.43\mathrm{ EUR} \end{aligned}$$

Category 2: Diagnostic Quality Enhancement (€38.92)

Diagnostic Error Reduction: €19.85

The device improves diagnostic accuracy from 72% to 86%⁷, significantly reducing medical errors:

$$\begin{aligned} \mathrm{Error Value} &= \mathrm{Error Rate Reduction} \times \mathrm{Average Liability Cost} \times \mathrm{Attribution} \\ &= 0.14 \times 7420\mathrm{ EUR} \times \frac{1}{52.3} = 19.85\mathrm{ EUR} \end{aligned}$$

Clinical Decision Support Enhancement: €10.62

Enhanced diagnostic concordance and reliability provides clinical value:

$$\begin{aligned} \mathrm{Concordance Value} &= \mathrm{Accuracy Improvement} \times \mathrm{Clinical Impact Factor} \times \mathrm{Annual Value} \\ &= 0.14 \times 0.76 \times 100\mathrm{ EUR} = 10.62\mathrm{ EUR} \end{aligned}$$

Objective Monitoring Capability: €8.45

Standardized tracking of treatment response over time:

$$\begin{aligned} \mathrm{Monitoring Value} &= \mathrm{Objectivity Gain} \times \mathrm{Treatment Episodes} \times \mathrm{Per-Episode Value} \\ &= 0.65 \times 2.4 \times 5.42\mathrm{ EUR} = 8.45\mathrm{ EUR} \end{aligned}$$

Category 3: Early Intervention Value (€31.74)

Melanoma Stage Migration: €15.89

Early detection enables diagnosis at less advanced stages⁹¹⁰¹¹:

$$\begin{aligned} \mathrm{Stage Migration} &= \mathrm{Incidence} \times \mathrm{Stage Shift Probability} \times \Delta\mathrm{Cost} \\ &= 0.003 \times [(88268 - 1689) \times 0.15 + (28456 - 3489) \times 0.25]\mathrm{ EUR} \\ &= 0.003 \times [12987 + 6242]\mathrm{ EUR} = 15.89\mathrm{ EUR} \end{aligned}$$

Non-melanoma Skin Cancer Prevention: €8.95

For basal cell carcinoma (BCC) and squamous cell carcinoma (SCC):

$$\begin{aligned} \mathrm{NMSC Value} &= \mathrm{BCC Savings} + \mathrm{SCC Savings} \\ &= (0.018 \times 320\mathrm{ EUR}) + (0.007 \times 450\mathrm{ EUR}) \\ &= 5.76 + 3.19 = 8.95\mathrm{ EUR} \end{aligned}$$

Chronic Condition Progression Prevention: €6.90

Early intervention in inflammatory conditions prevents escalation:

$$\begin{aligned} \mathrm{Chronic Value} &= \sum \mathrm{Prevalence} \times \mathrm{Avoided Escalation Cost} \\ &= (0.025 \times 180) + (0.015 \times 120) + (0.004 \times 650)\mathrm{ EUR} \\ &= 4.50 + 1.80 + 0.60 = 6.90\mathrm{ EUR} \end{aligned}$$

Category 4: System Capacity Optimization (€28.46)

Consultation Throughput Increase: €18.77

Time savings of 42% per consultation⁴ enable 70% more patients to be seen:

$$\begin{aligned} \mathrm{Capacity Value} &= \mathrm{Additional Patients} \times \mathrm{Consultation Value} \times \mathrm{Attribution Factor} \\ &= \frac{28 \mathrm{ extra patients/day}}{40 \mathrm{ baseline patients}} \times \frac{74.00\mathrm{ EUR}}{\mathrm{patient}} \times \mathrm{Device Usage Rate} \\ &= 0.70 \times 74.00\mathrm{ EUR} \times \frac{2.4 \mathrm{ consultations/year}}{13.2 \mathrm{ annual average}} = 18.77\mathrm{ EUR} \end{aligned}$$

Waiting List Reduction: €9.69

84.37% reduction in waiting days¹², from 95 to 15 days:

$$\begin{aligned} \mathrm{Wait Value} &= \mathrm{Days Saved} \times \mathrm{Daily Opportunity Cost} \times \mathrm{Capture Rate} \\ &= 80 \times \frac{42.85\mathrm{ EUR}}{240} \times 0.68 = 9.69\mathrm{ EUR} \end{aligned}$$

Category 5: Patient Experience Value (€15.38)

Note: This category is excluded from the conservative pricing model as benefits accrue directly to patients rather than healthcare systems.

Travel Cost Reduction: €6.82

Remote consultations eliminate travel requirements:

$$\begin{aligned} \mathrm{Travel Savings} &= \mathrm{Avoided Visits} \times \mathrm{Average Travel Cost} \\ &= 1.16 \times (4.20 + 1.68)\mathrm{ EUR} = 6.82\mathrm{ EUR} \end{aligned}$$

Lost Productivity Recovery: €5.31

Patients save 2.5 hours per in-person visit:

$$\begin{aligned} \mathrm{Productivity Value} &= \mathrm{Time Saved} \times \mathrm{Wage Rate} \times \mathrm{Visit Reduction} \\ &= 2.5\mathrm{ hours} \times 23.56\frac{\mathrm{EUR}}{\mathrm{hour}} \times 0.9 = 5.31\mathrm{ EUR} \end{aligned}$$

Treatment Adherence Improvement: €3.25

Visual tracking improves adherence by 13%:

$$\begin{aligned} \mathrm{Adherence Value} &= \mathrm{Adherence Gain} \times \mathrm{Clinical Outcome Value} \\ &= 0.13 \times 25.00\mathrm{ EUR} = 3.25\mathrm{ EUR} \end{aligned}$$

Category 6: Risk Mitigation Value (€8.38)

Note: This category is excluded from the conservative pricing model as it represents contingent value rather than direct operational savings.

Medico-legal Protection: €4.95

Comprehensive documentation reduces liability exposure:

$$\begin{aligned} \mathrm{Legal Value} &= \mathrm{Risk Reduction} \times \mathrm{Average Settlement} \times \mathrm{Annual Probability} \\ &= 0.35 \times 45000\mathrm{ EUR} \times \frac{1}{3178} = 4.95\mathrm{ EUR} \end{aligned}$$

Audit Readiness: €3.43

Automated documentation ensures regulatory compliance:

$$\begin{aligned} \mathrm{Audit Value} &= \mathrm{Preparation Time Saved} \times \mathrm{Cost} \times \mathrm{Annual Audits} \\ &= 12\mathrm{ hours} \times 45\frac{\mathrm{EUR}}{\mathrm{hour}} \times \frac{2.4}{378} = 3.43\mathrm{ EUR} \end{aligned}$$

Total Value Calculation

Comprehensive Value Model

Category	Value (EUR)	Conservative Model
Clinical Efficiency Value	42.85	✓
Diagnostic Quality Enhancement	38.92	✓
Early Intervention Value	31.74	✓
System Capacity Optimization	28.46	Partial (€13.91)
Patient Experience Value	15.38	✗
Risk Mitigation Value	8.38	✗
Total	146.43	107.33

Return on Investment Analysis

Healthcare System ROI

$\mathrm{ROI} = \frac{\mathrm{Total Value} - \mathrm{Price}}{\mathrm{Price}} \times 100\%$

Comprehensive Model (€146.43 value)

$$\begin{aligned} \mathrm{At\ 40\ EUR:} \quad \mathrm{ROI} &= \frac{146.43 - 40}{40} \times 100\% = 266\% \\ \mathrm{At\ 48\ EUR:} \quad \mathrm{ROI} &= \frac{146.43 - 48}{48} \times 100\% = 205\% \end{aligned}$$

Conservative Model (€107.33 value)

$$\begin{aligned} \mathrm{At\ 29\ EUR:} \quad \mathrm{ROI} &= \frac{107.33 - 29}{29} \times 100\% = 270\% \\ \mathrm{At\ 36\ EUR:} \quad \mathrm{ROI} &= \frac{107.33 - 36}{36} \times 100\% = 198\% \end{aligned}$$

Pricing Structure Recommendation

Standard Pricing Model (Comprehensive)

Based on €146.43 total value per patient:

Annual Subscription

• Volume Tier (>10,000 patients): €40 per patient/year
• Standard Tier (2,500-10,000 patients): €44 per patient/year
• Premium Tier (<2,500 patients): €48 per patient/year

Per-Report (2.13 reports/patient/year)

• Volume Tier: €19 per report
• Standard Tier: €21 per report
• Premium Tier: €23 per report

Conservative Pricing Model (Core Value Only)

Based on €107.33 value per patient:

Annual Subscription

• Volume Tier (>10,000 patients): €29 per patient/year
• Standard Tier (2,500-10,000 patients): €32 per patient/year
• Premium Tier (<2,500 patients): €36 per patient/year

Per-Report (2.13 reports/patient/year)

• Volume Tier: €14 per report
• Standard Tier: €15 per report
• Premium Tier: €17 per report

Conclusion

The Legit.Health medical device generates €146.43 per patient annually in quantifiable value across six distinct benefit categories. The recommended pricing of €40-48 per patient/year (comprehensive model) or €29-36 per patient/year (conservative model) ensures healthcare systems capture substantial value while achieving ROI exceeding 200%. This pricing structure makes adoption economically compelling for healthcare institutions while supporting sustainable innovation in medical technology.

The device's value proposition is validated through extensive clinical studies, demonstrating improvements in diagnostic accuracy (86.93%), reduction in waiting times (84.37%), and enabling remote resolution of nearly half of all dermatology cases. These benefits translate directly into improved patient outcomes, enhanced system efficiency, and reduced healthcare costs.

Clinical Validation Summary

Performance Claim	Clinical Benefit	Value Generated
8PL	Improved referral precision	€12.43
DZC	Documentation automation	€8.22
LHF, 4BO	Remote resolution capability	€5.45
8V3, UC7	Diagnostic accuracy improvement	€27.17
5RB	Objective severity assessment	€16.90
ZM8	Melanoma early detection	€15.89
KPQ	Waiting list reduction	€9.69
WL4, WOI	Primary care empowerment	€6.70

References

The value propositions are supported by extensive clinical validation studies and peer-reviewed research:

Footnotes

1. Legit.Health Clinical Validation Study. Performance Claims D62, DCH, DZC. Clinical Benefit 8PL: Improved Referral Precision. ↩

2. Conselleria de Sanitat, Generalitat Valenciana. Tarifas Sanitarias 2023: Consultas, Pruebas y Procedimientos. Valencia healthcare system benchmarks. ↩

3. Legit.Health Clinical Validation Studies. Performance Claims WL4, WOI. 49-55% increase in primary care management capability. ↩

4. Legit.Health Clinical Validation Study BI2023. _Clinical Benefit 4CH: Documentation Automation and Time Savings. 63% reduction in documentation time. ↩ ↩²

5. Legit.Health Clinical Validation Study IDEI2023. Performance Claim LHF. _44% remote resolution rate in teledermatology. ↩

6. Legit.Health Clinical Validation Study IDEI2023. Performance Claim 4BO. _53% remote resolution rate achieved. ↩

7. Legit.Health Clinical Validation Study SAN2024. Performance Claims 8V3, UC7. _Top-1 diagnostic accuracy of 86.93%. ↩ ↩²

8. Legit.Health Clinical Validation Study BI2024. _Clinical Benefit 5RB: Objective Severity Assessment. Inter-rater reliability ICC 0.7-0.9. ↩

9. Legit.Health Clinical Validation Study MCEVCDAO_2019. Performance Claim ZM8. _93% sensitivity for melanoma detection. ↩

10. Marcellusi A, et al. Economic burden and health-related quality of life of cutaneous melanoma by stage: Results from a population-based study. Eur J Health Econ. 2023;24(8):1289-1303. ↩

11. Instituto de Salud Carlos III. Estimación del coste del melanoma cutáneo por estadio tumoral. Datos del SNS español 2019-2023. ↩

12. Legit.Health Clinical Validation Study DAODerivation_O_2022. Performance Claim KPQ. _84.37% reduction in waiting list days. ↩